Nikhil Vaishnav Tirukkovalur

Nikhil Vaishnav Tirukkovalur

Auto-generated profile, based on publicly available information

Nikhil Vaishnav Tirukkovalur

Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
Purpose: Unsatisfactory outcomes in pancreatic ductal adenocarcinoma (PDAC) highlight the need to identify precision-based treatment modalities. We aimed to utilize patient-derived organoids (PDO) to predict the most effective individual components of potential combination therapies. Experimental Design: Autologous αβ- and γδ-enriched tumor-infiltrating lymphocyte (TIL) and PDO cultures were established from resected PDAC tissue. PDOs were characterized by immunostaining, targeted next-generation sequencing, and drug screening with standard-of-care multidrug chemotherapeutic regimens. Expanded TIL cultures were profiled through flow cytometry, sequencing, and potency against autologous PDOs. Results: PDO cultures were established with an 80% success rate. In addition to faithfully recapitulating molecular and histologic features of the parental tumor, PDOs were sufficiently expanded for pharmacotyping within a clinically relevant time frame of 36 days. Notably, PDO chemotherapeutic sensitivity profiles correlated with patient serum CA 19-9 dynamics and recurrence-free survival. Furthermore, expanded γδ-enriched TILs supported the activation of αβ TCR+ cells and demonstrated more potent functionality in response to autologous PDO targets. Importantly, infiltration of γδ T cells within pancreatic tumor tissue was associated with improved overall survival. Conclusions: We confirm the feasibility of generating PDOs within a clinically relevant time frame and provide evidence of their utility for advancing therapeutic success in PDAC.

8 September 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
JQJiage Qian
Jiage Qian
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
KLKenneth K. Lee
Kenneth K. Lee
AZAmer H. Zureikat
Amer H. Zureikat
APAlessandro Paniccia
Alessandro Paniccia
Prior evidence suggests higher postoperative complications in pancreatic neuroendocrine tumors (pNET) compared to ductal adenocarcinoma (PDAC). This study refines the comparison using the Ideal Outcome (IO) metric and identifies predictors of IO. A retrospective cohort study was performed using the 2014-2023 standard and pancreas-targeted ACS-NSQIP database to identify patients with PDAC or pNET who underwent pancreatoduodenectomy (PD) or distal pancreatectomy (DP). IO was defined as absence of clinically relevant postoperative pancreatic fistula (CR-POPF), prolonged length of stay (LOS), severe complications, reoperation, readmission, and mortality. A total of 25,290 PDAC and 4914 pNET patients were included. In PD, IO was lower in pNET (44.2 %) compared to PDAC (56.9 %, p < 0.001), with pNET having higher rates of severe complications (31.2 % vs. 19.0 %, p < 0.001), prolonged LOS (28.9 % vs. 25.8 %; p = 0.004), CR-POPF (26.7 % vs. 10.9 %; p < 0.001), and readmission (23.6 % vs. 15.3 %; p < 0.001). In contrast, pNET had higher IO after DP (60.1 % vs. 57.1 %; p = 0.008), with higher CR-POPF (19.2 % vs. 13.4 %; p < 0.001) but lower prolonged LOS (18.5 % vs. 26.4 %; p < 0.001). In PD, predictors of lower IO for both histologies included male sex (PDAC aOR 0.83; pNET 0.60), obesity (0.77; 0.63), hypertension (0.89; 0.79), small duct (0.81; 0.75), and soft gland (0.62; 0.57). In DP, minimally invasive surgery was associated with higher IO in both cancer types (PDAC aOR 1.71; pNET 1.52; all p < 0.05). Compared to PDAC, IO rate for pNET was lower after PD but higher after DP. CR-POPF was consistently higher in pNET, while other components of IO varied by procedure.

13 April 2025 in Exploration of digestive diseases
Verified
Journal Article
Open access
PDF file
RARudy El Asmar
Rudy El Asmar
NBNazih Bizri
Nazih Bizri
NTNikhil Vaishnav Tirukkovalur
Nikhil Vaishnav Tirukkovalur
ATAdam Tcharni
Adam Tcharni
NDNavya Dasyam
Navya Dasyam
SASamer AlMasri
Samer AlMasri
Pancreatic cystic lesions are frequently found incidentally on cross-sectional imaging and are broadly classified into mucinous and non-mucinous cysts. While some exhibit benign behavior, others have a malignant potential and are considered noninvasive precursors of pancreatic ductal adenocarcinoma. Guidelines from various societies propose risk stratification based on morphologic features and cyst fluid analysis. Fluid analysis through EUS-guided fine needle aspiration contributes to improved classification and recently, targeted DNA or RNA-based next generation sequencing is emerging as a critical investigation tool for diagnostic confirmation and risk stratification of pancreatic cysts. Each of these modalities has specific strengths and limitations, highlighting the need for a multi-modal approach for comprehensive assessment to guide clinical decision making. In this perspective, we aim to provide a thorough clinicopathologic framework for diagnosing and risk stratifying pancreatic cysts encompassing imaging findings, cyst fluid analyses, and next generation sequencing.

4 February 2026
Verified
Other
Open access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
Purpose:Unsatisfactory outcomes in pancreatic ductal adenocarcinoma (PDAC) highlight the need to identify precision-based treatment modalities. We aimed to utilize patient-derived organoids (PDO) to predict the most effective individual components of potential combination therapies.Experimental Design:Autologous αβ- and γδ-enriched tumor-infiltrating lymphocyte (TIL) and PDO cultures were established from resected PDAC tissue. PDOs were characterized by immunostaining, targeted next-generation sequencing, and drug screening with standard-of-care multidrug chemotherapeutic regimens. Expanded TIL cultures were profiled through flow cytometry, sequencing, and potency against autologous PDOs.Results:PDO cultures were established with an 80% success rate. In addition to faithfully recapitulating molecular and histologic features of the parental tumor, PDOs were sufficiently expanded for pharmacotyping within a clinically relevant time frame of 36 days. Notably, PDO chemotherapeutic sensitivity profiles correlated with patient serum CA 19-9 dynamics and recurrence-free survival. Furthermore, expanded γδ-enriched TILs supported the activation of αβ TCR+ cells and demonstrated more potent functionality in response to autologous PDO targets. Importantly, infiltration of γδ T cells within pancreatic tumor tissue was associated with improved overall survival.Conclusions:We confirm the feasibility of generating PDOs within a clinically relevant time frame and provide evidence of their utility for advancing therapeutic success in PDAC.

4 February 2026
Verified
Other
Open access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
Patient demographic and clinicopathological characteristics

4 February 2026
Verified
Other
Open access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
Gating strategy for the phenotyping of TIL cultures at REP day 14 by spectral cytometry